fluoropyrimidine, HER2-positive, oxaliplatin, Seagen Inc, tucatinib, Tukysa
Accelerated approval is granted by FDA to tucatinib with trastuzumab for colorectal cancer
In February 2023, the Food and Drug Administration (FDA) sped up the approval of tucatinib (Tukysa, Seagen Inc.) and trastuzumab for the treatment of RAS wild-type HER2-positive colorectal cancer that has spread or can not be rem..
Adcetris, brentuximab vedotin, classical Hodgkin lymphoma, Seagen Inc
Brentuximab vedotin is approved by FDA in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma
November 2022: The combination of doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide with brentuximab vedotin (Adcetris, Seagen, Inc.) has been approved by the Food and Drug Administration for use in children an..